166 related articles for article (PubMed ID: 23265697)
1. Biologics and the treatment of chronic rhinosinusitis.
Kern RC
J Allergy Clin Immunol; 2013 Jan; 131(1):117-8. PubMed ID: 23265697
[No Abstract] [Full Text] [Related]
2. Should clinicians use omalizumab for the treatment of nasal polyps?
Naclerio RM; Baroody FM; Pinto JM
J Allergy Clin Immunol; 2013 Jul; 132(1):247. PubMed ID: 23684073
[No Abstract] [Full Text] [Related]
3. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
Gevaert P; Calus L; Van Zele T; Blomme K; De Ruyck N; Bauters W; Hellings P; Brusselle G; De Bacquer D; van Cauwenberge P; Bachert C
J Allergy Clin Immunol; 2013 Jan; 131(1):110-6.e1. PubMed ID: 23021878
[TBL] [Abstract][Full Text] [Related]
4. Reply: To PMID 23021878.
Calus L; Hellings P; Brusselle G; Bachert C; Gevaert P
J Allergy Clin Immunol; 2013 Jul; 132(1):247-8. PubMed ID: 23684071
[No Abstract] [Full Text] [Related]
5. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma.
Tajiri T; Matsumoto H; Hiraumi H; Ikeda H; Morita K; Izuhara K; Ono J; Ohta S; Ito I; Oguma T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Ito J; Niimi A; Mishima M
Ann Allergy Asthma Immunol; 2013 May; 110(5):387-8. PubMed ID: 23622013
[No Abstract] [Full Text] [Related]
6. Omalizumab for severe allergic asthma: 7 years and open questions.
Solèr M
Respiration; 2014; 88(2):158-61. PubMed ID: 24818580
[TBL] [Abstract][Full Text] [Related]
7. Allergic asthma and omalizumab--the experience at the Centro Hospitalar da Cova da Beira.
Simões Saldanha Mendes M; Valente MJ; Vicente I; Magalhães E; Valente S
Rev Port Pneumol; 2013; 19(4):186-7. PubMed ID: 23731772
[No Abstract] [Full Text] [Related]
8. Echinococcus multilocularis infection in a patient treated with omalizumab.
Skiepko R; Zietkowski Z; Skiepko U; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A
J Investig Allergol Clin Immunol; 2013; 23(3):199-200. PubMed ID: 23967760
[No Abstract] [Full Text] [Related]
9. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis.
Matito A; Blázquez-Goñi C; Morgado JM; Alvarez-Twose I; Mollejo M; Sánchez-Muñoz L; Escribano L
Ann Allergy Asthma Immunol; 2013 Nov; 111(5):425-6. PubMed ID: 24125156
[No Abstract] [Full Text] [Related]
10. Efficacy of omalizumab in the treatment of nasal polyps.
Vennera Mdel C; Picado C; Mullol J; Alobid I; Bernal-Sprekelsen M
Thorax; 2011 Sep; 66(9):824-5. PubMed ID: 21109700
[No Abstract] [Full Text] [Related]
11. Basophil activation test: do not lose control.
Maietta G
Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):36-7. PubMed ID: 25781191
[No Abstract] [Full Text] [Related]
12. [Dermatological implications of omalizumab, an anti-IgE antibody].
Di Lucca-Chrisment J
Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140
[TBL] [Abstract][Full Text] [Related]
13. Identifying Patients for Self-Administration of Omalizumab.
Murphy KR; Winders T; Smith B; Millette L; Chipps BE
Adv Ther; 2023 Jan; 40(1):19-24. PubMed ID: 36173511
[TBL] [Abstract][Full Text] [Related]
14. Anti-IgE--emerging opportunities for Omalizumab.
Babu KS; Polosa R; Morjaria JB
Expert Opin Biol Ther; 2013 May; 13(5):765-77. PubMed ID: 23517576
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab for chronic urticaria.
Altman MC; Naimi DR
N Engl J Med; 2013 Jun; 368(26):2528-30. PubMed ID: 23802532
[No Abstract] [Full Text] [Related]
16. Omalizumab for chronic urticaria.
Benelli E; Ventura A
N Engl J Med; 2013 Jun; 368(26):2528. PubMed ID: 23802531
[No Abstract] [Full Text] [Related]
17. Omalizumab for chronic urticaria.
Wu K; Long H
N Engl J Med; 2013 Jun; 368(26):2527-8. PubMed ID: 23802530
[No Abstract] [Full Text] [Related]
18. Omalizumab for chronic urticaria.
Maurer M; Rosén K; Hsieh HJ
N Engl J Med; 2013 Jun; 368(26):2530. PubMed ID: 23802529
[No Abstract] [Full Text] [Related]
19. Can omalizumab be effective in chronic eosinophilic pneumonia?
Domingo C; Pomares X
Chest; 2013 Jan; 143(1):274. PubMed ID: 23276861
[No Abstract] [Full Text] [Related]
20. Differences in effects of omalizumab on late-phase responses to allergen challenge in the skin and nose at the time of basophil hyporesponsiveness.
Paterniti MO; Breslin LM; Courneya JP; Sterba PM; Hamilton RG; MacGlashan DW; Saini SS
J Invest Dermatol; 2014 Jun; 134(6):1743-1744. PubMed ID: 24366613
[No Abstract] [Full Text] [Related]
[Next] [New Search]
